ALKS Market Analysis
Wall Street coverage
third-party contextWall Street coverage
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
News & Sentiment
50 articles · sorted by dateVia 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Fundamentals
Updated daily after market closeValuation
- Forward P/E
- 133.33
- PEG ratio
- 1.96
- P/B
- 4.54
- P/S (TTM)
- 4.93
- EV/EBITDA
- 41.89
Profitability & growth
- ROE (TTM)
- 3.9%
- Operating margin
- 15.5%
- Revenue growth YoY
- 27.0%
- Dividend yield
- —
- Beta
- 0.29
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About Alkermes Plc
Company profileAlkermes plc, a biopharmaceutical company, researches, develops and markets pharmaceutical products to address the unmet medical needs of patients in various therapeutic areas in the United States, Ireland and internationally. The company is headquartered in Dublin, Ireland.
Classification
- Sector
- Healthcare
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- CONNAUGHT HOUSE, DUBLIN, IRELAND
- Fiscal year end
- December
- Latest quarter
- Jun 30, 2026
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
